サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1746489

日本のファーマコビジランス市場レポート：サービスプロバイダー別、製品ライフサイクル別、タイプ別、プロセスフロー別、治療領域別、最終用途別、地域別、2025年～2033年

Japan Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 120 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.42円
日本のファーマコビジランス市場レポート：サービスプロバイダー別、製品ライフサイクル別、タイプ別、プロセスフロー別、治療領域別、最終用途別、地域別、2025年～2033年
出版日: 2025年06月02日
発行: IMARC
ページ情報: 英文 120 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本のファーマコビジランス市場規模は2024年に5億270万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに9億7,610万米ドルに達し、2025～2033年の成長率（CAGR）は7.70％を示すと予測しています。ビッグデータ分析、人工知能、機械学習ツールに対する需要の高まりは、より効率的な信号検出とリスク評価を可能にすることでファーマコビジランスに革命をもたらし、市場を牽引しています。

本レポートで扱う主な質問

  • 日本のファーマコビジランス市場はこれまでどのように推移し、今後どのように推移していくのか？
  • COVID-19が日本のファーマコビジランス市場に与えた影響は？
  • 日本のファーマコビジランス市場のサービスプロバイダー別区分は？
  • 日本のファーマコビジランス市場の製品ライフサイクル別区分は？
  • 日本のファーマコビジランス市場のタイプ別区分は？
  • 日本のファーマコビジランス市場のプロセスフロー別区分は？
  • 日本のファーマコビジランス市場の治療領域別内訳は？
  • 日本のファーマコビジランス市場のエンドユーズ別の区分は？
  • 日本のファーマコビジランス市場のバリューチェーンにおける様々なステージとは？
  • 日本のファーマコビジランスの主要な促進要因と課題は何か？
  • 日本のファーマコビジランス市場の構造と主要プレーヤーは？
  • 日本のファーマコビジランス市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本のファーマコビジランス市場- イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本のファーマコビジランス市場情勢

  • 過去および現在の市場動向（2019～2024年）
  • 市場予測（2025～2033年）

第6章 日本のファーマコビジランス市場- サービスプロバイダー別の内訳

  • 社内
  • 契約アウトソーシング

第7章 日本のファーマコビジランス市場- 製品ライフサイクル別の内訳

  • 前臨床
  • フェーズI
  • フェーズII
  • フェーズIII
  • フェーズIV

第8章 日本のファーマコビジランス市場- タイプ別の内訳

  • 自発報告
  • ADR報告の強化
  • 対象を絞った自発報告
  • コホートイベントモニタリング
  • EHRマイニング

第9章 日本のファーマコビジランス市場- プロセスフロー別の内訳

  • ケースデータ管理
  • 信号検出
  • リスク管理システム

第10章 日本のファーマコビジランス市場- 治療領域別の内訳

  • 腫瘍学
  • 神経学
  • 心臓病学
  • 呼吸器系
  • その他

第11章 日本のファーマコビジランス市場- 最終用途別の内訳

  • 製薬会社
  • バイオテクノロジー企業
  • 医療機器企業
  • その他

第12章 日本のファーマコビジランス市場- 競合情勢

  • 概要
  • 市場構造
  • 市場企業のポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第13章 主要企業のプロファイル

第14章 日本のファーマコビジランス市場- 業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第15章 付録

目次
Product Code: SR112025A19290

Japan pharmacovigilance market size reached USD 502.7 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 976.1 Million by 2033, exhibiting a growth rate (CAGR) of 7.70% during 2025-2033. The increasing demand for big data analytics, artificial intelligence, and machine learning tools, which has revolutionized pharmacovigilance by enabling more efficient signal detection and risk assessment, is driving the market.

Pharmacovigilance is a crucial aspect of healthcare and drug regulation. It involves the systematic monitoring, assessment, and reporting of adverse effects and safety concerns associated with pharmaceutical products, including prescription medications, vaccines, and over-the-counter drugs. The primary goal of pharmacovigilance is to ensure the safety and effectiveness of these products throughout their lifecycle. Healthcare professionals, pharmaceutical companies, and regulatory agencies collaborate in this process. They collect and analyze data on adverse events and side effects reported by patients and healthcare providers. If a potential safety concern arises, appropriate actions, such as product labeling updates, warnings, or even product recalls, may be taken to protect public health. Pharmacovigilance helps identify previously unknown or rare adverse effects, ensuring that drugs on the market remain safe for patients. This ongoing monitoring and risk assessment contribute to the continuous improvement of drug safety and the overall quality of healthcare.

Japan Pharmacovigilance Market Trends:

The pharmacovigilance market in Japan is experiencing robust growth, primarily due to several interconnected drivers. Firstly, the escalating regional demand for healthcare services has led to an increased consumption of medicines, amplifying the need for vigilant monitoring of drug safety. Additionally, the rising prevalence of chronic diseases and the introduction of new and complex therapies have further fueled the expansion of the pharmacovigilance market. Moreover, regulatory agencies in Japan are tightening their oversight of drug safety, imposing stringent reporting requirements on pharmaceutical companies. This has necessitated the outsourcing of pharmacovigilance activities to specialized service providers, driving market growth. Simultaneously, the growing awareness among healthcare professionals and patients about the importance of adverse event reporting has led to increased pharmacovigilance efforts. Moreover, advancements in technology, including artificial intelligence and big data analytics, which have revolutionized pharmacovigilance by enhancing the efficiency and accuracy of adverse event detection, are expected to drive the market in Japan during the forecast period.

Japan Pharmacovigilance Market Segmentation:

Service Provider Insights:

  • In-house
  • Contract Outsourcing

Product Life Cycle Insights:

  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Type Insights:

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Process Flow Insights:

  • Case Data Management
    • Case Logging
    • Case Data Analysis
    • Medical Reviewing and Reporting
  • Signal Detection
    • Adverse Event Logging
    • Adverse Event Analysis
    • Adverse Event Review and Reporting
  • Risk Management System
    • Risk Evaluation System
    • Risk Mitigation System

Therapeutic Area Insights:

  • Oncology
  • Neurology
  • Cardiology
  • Respiratory Systems
  • Others

End Use Insights:

  • Pharmaceuticals Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan pharmacovigilance market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan pharmacovigilance market?
  • What is the breakup of the Japan pharmacovigilance market on the basis of service provider?
  • What is the breakup of the Japan pharmacovigilance market on the basis of product life cycle?
  • What is the breakup of the Japan pharmacovigilance market on the basis of type?
  • What is the breakup of the Japan pharmacovigilance market on the basis of process flow?
  • What is the breakup of the Japan pharmacovigilance market on the basis of therapeutic area?
  • What is the breakup of the Japan pharmacovigilance market on the basis of end use?
  • What are the various stages in the value chain of the Japan pharmacovigilance market?
  • What are the key driving factors and challenges in the Japan pharmacovigilance?
  • What is the structure of the Japan pharmacovigilance market and who are the key players?
  • What is the degree of competition in the Japan pharmacovigilance market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacovigilance Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Pharmacovigilance Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Pharmacovigilance Market - Breakup by Service Provider

  • 6.1 In-house
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Contract Outsourcing
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)

7 Japan Pharmacovigilance Market - Breakup by Product Life Cycle

  • 7.1 Pre-clinical
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Phase I
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Phase II
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Forecast (2025-2033)
  • 7.4 Phase III
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2019-2024)
    • 7.4.3 Market Forecast (2025-2033)
  • 7.5 Phase IV
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2019-2024)
    • 7.5.3 Market Forecast (2025-2033)

8 Japan Pharmacovigilance Market - Breakup by Type

  • 8.1 Spontaneous Reporting
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 Intensified ADR Reporting
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Targeted Spontaneous Reporting
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)
  • 8.4 Cohort Event Monitoring
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2019-2024)
    • 8.4.3 Market Forecast (2025-2033)
  • 8.5 EHR Mining
    • 8.5.1 Overview
    • 8.5.2 Historical and Current Market Trends (2019-2024)
    • 8.5.3 Market Forecast (2025-2033)

9 Japan Pharmacovigilance Market - Breakup by Process Flow

  • 9.1 Case Data Management
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2019-2024)
    • 9.1.3 Market Segmentation
      • 9.1.3.1 Case Logging
      • 9.1.3.2 Case Data Analysis
      • 9.1.3.3 Medical Reviewing and Reporting
    • 9.1.4 Market Forecast (2025-2033)
  • 9.2 Signal Detection
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2019-2024)
    • 9.2.3 Market Segmentation
      • 9.2.3.1 Adverse Event Logging
      • 9.2.3.2 Adverse Event Analysis
      • 9.2.3.3 Adverse Event Review and Reporting
    • 9.2.4 Market Forecast (2025-2033)
  • 9.3 Risk Management System
    • 9.3.1 Overview
    • 9.3.2 Historical and Current Market Trends (2019-2024)
    • 9.3.3 Market Segmentation
      • 9.3.3.1 Risk Evaluation System
      • 9.3.3.2 Risk Mitigation System
    • 9.3.4 Market Forecast (2025-2033)

10 Japan Pharmacovigilance Market - Breakup by Therapeutic Area

  • 10.1 Oncology
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2019-2024)
    • 10.1.3 Market Forecast (2025-2033)
  • 10.2 Neurology
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2019-2024)
    • 10.2.3 Market Forecast (2025-2033)
  • 10.3 Cardiology
    • 10.3.1 Overview
    • 10.3.2 Historical and Current Market Trends (2019-2024)
    • 10.3.3 Market Forecast (2025-2033)
  • 10.4 Respiratory Systems
    • 10.4.1 Overview
    • 10.4.2 Historical and Current Market Trends (2019-2024)
    • 10.4.3 Market Forecast (2025-2033)
  • 10.5 Others
    • 10.5.1 Historical and Current Market Trends (2019-2024)
    • 10.5.2 Market Forecast (2025-2033)

11 Japan Pharmacovigilance Market - Breakup by End Use

  • 11.1 Pharmaceuticals Companies
    • 11.1.1 Overview
    • 11.1.2 Historical and Current Market Trends (2019-2024)
    • 11.1.3 Market Forecast (2025-2033)
  • 11.2 Biotechnology Companies
    • 11.2.1 Overview
    • 11.2.2 Historical and Current Market Trends (2019-2024)
    • 11.2.3 Market Forecast (2025-2033)
  • 11.3 Medical Device Companies
    • 11.3.1 Overview
    • 11.3.2 Historical and Current Market Trends (2019-2024)
    • 11.3.3 Market Forecast (2025-2033)
  • 11.4 Others
    • 11.4.1 Historical and Current Market Trends (2019-2024)
    • 11.4.2 Market Forecast (2025-2033)

12 Japan Pharmacovigilance Market - Competitive Landscape

  • 12.1 Overview
  • 12.2 Market Structure
  • 12.3 Market Player Positioning
  • 12.4 Top Winning Strategies
  • 12.5 Competitive Dashboard
  • 12.6 Company Evaluation Quadrant

13 Profiles of Key Players

  • 13.1 Company A
    • 13.1.1 Business Overview
    • 13.1.2 Services Offered
    • 13.1.3 Business Strategies
    • 13.1.4 SWOT Analysis
    • 13.1.5 Major News and Events
  • 13.2 Company B
    • 13.2.1 Business Overview
    • 13.2.2 Services Offered
    • 13.2.3 Business Strategies
    • 13.2.4 SWOT Analysis
    • 13.2.5 Major News and Events
  • 13.3 Company C
    • 13.3.1 Business Overview
    • 13.3.2 Services Offered
    • 13.3.3 Business Strategies
    • 13.3.4 SWOT Analysis
    • 13.3.5 Major News and Events
  • 13.4 Company D
    • 13.4.1 Business Overview
    • 13.4.2 Services Offered
    • 13.4.3 Business Strategies
    • 13.4.4 SWOT Analysis
    • 13.4.5 Major News and Events
  • 13.5 Company E
    • 13.5.1 Business Overview
    • 13.5.2 Services Offered
    • 13.5.3 Business Strategies
    • 13.5.4 SWOT Analysis
    • 13.5.5 Major News and Events

14 Japan Pharmacovigilance Market - Industry Analysis

  • 14.1 Drivers, Restraints, and Opportunities
    • 14.1.1 Overview
    • 14.1.2 Drivers
    • 14.1.3 Restraints
    • 14.1.4 Opportunities
  • 14.2 Porters Five Forces Analysis
    • 14.2.1 Overview
    • 14.2.2 Bargaining Power of Buyers
    • 14.2.3 Bargaining Power of Suppliers
    • 14.2.4 Degree of Competition
    • 14.2.5 Threat of New Entrants
    • 14.2.6 Threat of Substitutes
  • 14.3 Value Chain Analysis

15 Appendix